Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?

Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?

Source: 
Clinical Trials Arena
snippet: 

According to GlobalData, global sales for Trodelvy are expected to reach nearly $3bn by 2029, driven by expansion into new indications such as NSCLC.